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Computational Fluid Dynamics (CFD) Simulation is used to predict uniformity of biological formulations and 
impact from mixing equipment changes. Such changes occur during process transfer from one site to the other 
or upon batch size alterations.  Experimental runs are traditionally required during such switch, which could be 
expensive and resource-intensive, especially if it occurs in a commercial manufacture environment. The current 
study is aimed to reduce the number of experimental runs at scale by using CFD.  Steady state CFD mixing 
models are developed at smaller scales using physical properties of surrogate fluids. Experimental runs are 
designed and conducted to verify the validity of assumption made in the CFD models, such as the negligibility of 
starting period. The results show that assumptions made in the CFD models are valid and the CFD models yield 
outcomes similar to that of experiment, i.e., a tracer is uniformly distributed at similar time frame between the 
CFD simulations and the corresponding experiments. Large scale mixing models are further developed and 
used to support an equipment change as well as a batch size increase in the same mixer while mixing 
parameters are requested to be maintained. The CFD simulation suggest there is negligible impact in both 
cases and mixing process parameters can be maintained. Validation of the CFD models at the large scale with 
experiment is planned.  
 
